Source: Eur Respir J 2015; 46: 1046-1054
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Barr Helen L., Halliday Nigel, Cámara Miguel, Barrett David A., Williams Paul, Forrester Douglas L., Simms Rebecca, Smyth Alan R., Honeybourne David, Whitehouse Joanna L., Nash Edward F., Dewar Jane, Clayton Andrew, Knox Alan J., Fogarty Andrew W.. Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis. Eur Respir J 2015; 46: 1046-1054

Member's Comments

No comment yet.

Related content which might interest you: Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis Source: Eur Respir J 2005; 26: 651-656 Year: 2005 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Does sputum induction improve Pseudomonas aeruginosa detection in cystic fibrosis? Source: Eur Respir J 2003; 22: Suppl. 45, 231s Year: 2003 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis Source: Virtual Congress 2021 – Back to infection basics Year: 2021 Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Systemic quorum sensing signal molecules are biomarkers for current and future P. aeruginosa infection in cystic fibrosis patients: A longitudinal study Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Targeting iron uptake to control Pseudomonas aeruginosa infections in cystic fibrosis Source: Eur Respir J 2013; 42: 1723-1736 Year: 2013 Characterization of the resistance mechanisms to carbapenems and virulence genes in Pseudomonas aeruginosa strains from children with cystic fibrosis. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017 Year: 2017 Eradication of Pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2006; 27: 653 Year: 2006 Epidemiological-molecular study of colonization by pseudomonas aeruginosa in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 379s Year: 2002 Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Source: Eur Respir J 2006; 28: 974-979 Year: 2006 Eradication of Pseudomonas aeruginosa in cystic fibrosis Source: Eur Respir J 2006; 27: 438-439 Year: 2006